Compare CRI & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRI | GLUE |
|---|---|---|
| Founded | 1865 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2002 | 2021 |
| Metric | CRI | GLUE |
|---|---|---|
| Price | $38.42 | $16.48 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $35.60 | $32.00 |
| AVG Volume (30 Days) | 838.7K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $2,898,426,000.00 | $123,672,000.00 |
| Revenue This Year | $4.57 | N/A |
| Revenue Next Year | $1.12 | $2.45 |
| P/E Ratio | $96.00 | ★ $72.42 |
| Revenue Growth | 1.91 | ★ 63.54 |
| 52 Week Low | $23.68 | $4.12 |
| 52 Week High | $44.44 | $25.77 |
| Indicator | CRI | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 28.66 |
| Support Level | $37.18 | $14.77 |
| Resistance Level | $39.16 | $17.99 |
| Average True Range (ATR) | 1.78 | 1.45 |
| MACD | -0.02 | -0.73 |
| Stochastic Oscillator | 58.93 | 11.56 |
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).